A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 6, 1996, Pages 581-586

  Meropol, Neal J ^a   Rustum, Yousef M ^a   Petrelli, Nicholas J ^a   Rodriguez Bigas, Miguel ^a   Frank, Cheryl ^a   Ho, Dah H ^b   Kurowski, Marilyn ^a   Creaven, Patrick J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Ftorafur; Leucovorin; Uracil

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; FLUOROURACIL; FOLINIC ACID; TEGAFUR; URACIL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG BLOOD LEVEL; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; HYPERBILIRUBINEMIA; LEUCOVORIN; MALE; MIDDLE AGED; TEGAFUR; TETRAHYDROFOLATES; URACIL;

EID: 0029972388     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050432     Document Type: Article

References (28)

1. Ansfield FJ, Kallas GJ, Singson JP (1983) Phase I-II studies of oral tegafur (ftorafur). J Clin Oncol I:107
2. Cancer Therapy Evaluation Program (1989) Common toxicity criteria. In: NCI decision of cancer treatment guidelines for reporting of adverse drug reactions, July 6. NIH Publications. Bethesda
3. Creaven PJ, Rustum YM, Petrelli NJ, Gorbunova VA (1993) Clinical studies of the modulation of ftorafur. In: Rustum YM (ed) Novel approaches to selective treatments of human solid tumors: laboratory and clinical correlation. Plenum Press, New York, p 253
4. Creaven PJ, Rustum YM, Petrelli NJ, Meropol NJ, Raghavan D, Rodriguez-Bigas M, Levine EG, Frank C, Udvary-Nagy S, Proefrock A (1994) Phase I and pharmacokinetic evaluation of floxuridine leucovorin given on the Roswell Park weekly regimen. Cancer Chemother Pharmacol 34:261
5. Daniels M, Diaz-Rubio E, Guillem V, Montero JM, Garcia-Conde J, Estape J, Martin M, Herranz C, Ordonez A, Galan A (1993) Phase II trial of UFT activity in pretreated breast cancer patients. Jpn J Clin Oncol 23:363
6. Erlichman C, Marsoni S, Seitz JF, Skillings J, Shepherd L, Zee B, Milan C, Bedenne L, Giovanni M, Pienkowski P, Torri V, Tardio B, Smerieri F, Pancera G, Martignoni G (1994) Event free and overall survival is increased by fufa in resected b and c colon cancer: a prospective pooled analysis of 3 randomized trials (RCTS). Proc Am Soc Clin Oncol 13:194
7. Francini G, Petrioli R, Marsili S, Aquino A, Lorenzini L, Mancini S, Marzocca G, Lorenzi M, Armenio S, Tanzini G, Civitelli S, Mariani L, DeSando D, Bovenga S (1994) Folinic acid plus 5-fluorouracil as adjuvant chemotherapy in colon cancer. Proc Am Soc Clin Oncol 13:196
8. Friedman MA, Ignoffo RJ (1980) A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958). Cancer Treat Rev 7:205
9. Fujh S, Ikenaka K, Masakazu F, Shirasaka T (1978) Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 69:763
10. Fujh S, Kitano S, Ikenaka K, Shirasaka T (1979) Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-flourouracil in rodents. Gann 70:209
11. Gonzalez-Baron M, Ordonez FA, Colmenarijo A, Espinosa E, Zamora P, Gandara I de la, Jalon JI (1993) Phase I study of UFT plus leucovorin in advanced colorectal cancer:a double modulation proposal. Anticancer Res 13:759
12. Kajanti MJ, Pyrhonen SO, Maiche AG (1993) Oral tegafur in the treatment of metastatic breast cancer: a phase II study. Eur J Cancer 29A:863
13. Kawaguchi Y, Nagayama S, Masuda H, Yasuda A (1980) Studies on the metasbolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats. Gann 71:889
14. Laufman LR, Bukowski RM, Collier MA, Sullivan BA, McKinnis RA, Clendennin NJ, Guaspari A, Brenckman WD Jr (1993) A randomized, double-blind trial of fluorouracil plus palcebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 11:1888
15. Leichman CG, Fleming TR, Muggia FM, Ardalan B, Doroshow J, Tangen C, Macdonald J (1993) Fluorouracil (5-FU) schedules and modulation in advanced colorectal cancer (CRC): a southwest oncology group (SWOG) screening trial. Proc Am Soc Clin Oncol 12:198
16. Malik STA, Talbot D, Clarke PI, Osborne R, Reznek R, Wriglev PFM, Slevin ML (1990) Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 62:1023
17. Marunaka T, Umeno Y, Yoshida K, Nagamachi M, Minami Y, Fujii S (1980) High pressure liquid chromatographic determination of ftorafur [1-(tetrahydro-2furany)-5-fluorouracil] and GLC-mass spectrometric determination of 5-fluorouracil and uracil in biological materials after oral administration of uracil plus ftorafur. J Pharmacol Sci 69:1296
18. Muggia FM, Jeffers S, Leichman CG, Tulpule A, Hanisch R, Fuerst M, Spears CP, Wu XY, Chan K, Spicer D, Leichman L (1992) Potential for uracil + ftorafur (UFT) to mimic protracted infusions of 5-fluorouracil (FU). Proc Am Soc Clin Oncol 11:362
19. O'Connell M, Mailliard J, Macdonald J, Haller D, Mayer R, Wieand H (1993) An intergroup trial of intensive course 5FU and low dose leucovorin as surgical adjuvant therapy for high risk colon cancer. Proc Am Soc Clin Oncol 12:190
20. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, MacDonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502
21. Ota K, Taguchi T, Kimura K (1988) Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22:333
22. Pazdur R, Ho DH, Lassere Y, Bready B, Krakoff IH, Raber MN (1992) Phase I trial of oral ftorafur (FT) and uracil. Proc Am Soc Clin Oncol 11:265
23. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL, Bready B, Levin B (1994) Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12:2296
24. Piedbois P, Buyse M, Rustum YM, Machover D, Erlichman C, Carlson RW, Valone F, Labianca R, Doroshow JH, Petrelli N (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 6:896
25. Rustum YM, Cao S, Creaven PJ, Petrelli NJ (1993) Phase 1 clinical trials and pharmacokinetics of uracil-ftorafur combination (UFT) + leucovorin (LV) in patients with advanced colorectal cancer. Ther Res 14:2369
26. Straw JA, Szapary D, Wynn WT (1984) Pharmacokinetics of the diastercoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res 44:3114
27. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ, Spurr CL, Dimitrov N, Romond EH, Sutherland CM, Kardinal CG, DeFusco PA, Jochimsen P (1993) The benefit of leucovorin-modulated fluourouracil as postoperative adjuvant therapy for primary colon cancer: results from national surgical adjuvant breast and bowel project protocol C-03. J Clin Oncol 11:1879
28. Zhang Z-G, Rustum YM (1991) Effects of diastercoisomers of 5-formyltetrahydrofolate on cellular growth. Sensitivity to 5-fluoro-2′-deoxyuridine, and methylenetetrahydrofolate polyglutamate levels in HCT-8 cells. Cancer Res 51:3476